ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1730

Good Control of Inflammation Counterbalances a Negative Impact of Radiographic Spinal Progression on Functional Status and Spinal Mobility in Patients with Ankylosing Spondylitis Treated with TNF Inhibitors

Denis Poddubnyy1, Aleksandra Fedorova1, Joachim Listing2, Hildrun Haibel1, Xenofon Baraliakos3, Jürgen Braun3 and Joachim Sieper1, 1Charité Universitätsmedizin Berlin, Berlin, Germany, 2German Rheumatism Research Centre, Berlin, Germany, 3Rheumazentrum Ruhrgebiet, Herne, Germany

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Ankylosing spondylitis (AS) and spondylarthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 9, 2015

Title: Spondylarthropathies and Psoriatic Arthritis - Comorbidities and Treatment Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:

Impaired function and spinal
mobility in patients with ankylosing spondylitis (AS) can be
caused
by both spinal inflammation and new bone formation. Anti-TNF
therapy has been shown to reduce inflammation but the influence
on radiographic progression is less clear. The aim of the study was to
investigate the impact of long-term (up to 10 years) anti-TNF therapy on
function and spinal mobility in relation to radiographic progression in the
spine in patients with AS.

Methods:

Altogether 60 patients with AS from two long-term trials with
TNF blockers (43 on infliximab and 17 on etanercept)
were included in this analysis based on
availability of spinal x-rays performed at
baseline and at least at one following time-point (year 2, 4, 6, 8, 10) during
the follow-up.
Spinal
radiographs (cervical and lumbar spine lateral views) were scored according to the modified
Stoke Ankylosing Spondylitis Spine Score (mSASSS) system by two readers (DP and
AF) not blinded for the time point. The functional status was assessed by means
of the Bath Ankylosing Spondylitis Functional Index (BASFI), spinal mobility –
by the Bath Ankylosing Spondylitis Metrology Index (BASMI, 0-10), and clinical
disease activity – by the Bath Ankylosing Spondylitis Disease Activity Index
(BASDAI).

Results:

Patients treated with infliximab and
etanercept had similar baseline characteristics with regards of age, gender,
HLA-B27 status, symptom duration, disease activity and baseline structural
damage that allowed pooling of the data. After the BASFI, BASMI, and BASDAI had
initially improved significantly in response to anti-TNF therapy these two
outcome parameters remained remarkably stable at low levels over 10 years in
those patients who remained on the drug over time despite the observed mean
increase of the mSASSS by 6 points. The cumulative
probability plots (figure) demonstrate no increase of BASFI and BASMI with
increasing mSASSS. In the multivariate analysis
, there was no association between mSASSS change and BASFI change, while there was some impact
of the mSASSS change on BASMI change over time
(table). BASDAI demonstrated a strong association with functional status and,
to a lesser extent, with spinal mobility.

Conclusion:

Functional status in patients with
advanced AS remained stable during long-term anti-TNF therapy despite
radiographic progression. Under these conditions, the BASFI course correlated
strongly with BASDAI but not with the mSASSS. This might indicate that a good
control of inflammation is able to overweight the negative effect of structural
damage in the spine on the functional status in AS.

aTNF_Function_Figure

aTNF_Function_Table


Disclosure: D. Poddubnyy, AbbVie, MSD, Pfizer, UCB, 5; A. Fedorova, None; J. Listing, AbbVie, Celltrion, Hospira, MSD, Pfizer, UCB, 2,Pfizer, 5; H. Haibel, AbbVie, MSD, Pfizer, 5; X. Baraliakos, AbbVie, MSD, Pfizer, UCB, 5; J. Braun, AbbVie, MSD, Pfizer, UCB, 5,AbbVie, MSD, Pfizer, 2; J. Sieper, AbbVie, MSD, Pfizer, UCB, 5,AbbVie, MSD, Pfizer, 2.

To cite this abstract in AMA style:

Poddubnyy D, Fedorova A, Listing J, Haibel H, Baraliakos X, Braun J, Sieper J. Good Control of Inflammation Counterbalances a Negative Impact of Radiographic Spinal Progression on Functional Status and Spinal Mobility in Patients with Ankylosing Spondylitis Treated with TNF Inhibitors [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/good-control-of-inflammation-counterbalances-a-negative-impact-of-radiographic-spinal-progression-on-functional-status-and-spinal-mobility-in-patients-with-ankylosing-spondylitis-treated-with-tnf-inhi/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/good-control-of-inflammation-counterbalances-a-negative-impact-of-radiographic-spinal-progression-on-functional-status-and-spinal-mobility-in-patients-with-ankylosing-spondylitis-treated-with-tnf-inhi/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology